

## CONTENTS

### Advances in Brief

- 2187 Platelet: Transporter of Vascular Endothelial Growth Factor.** Henk M. W. Verheul, Klaas Hoekman, Sylvia Luykx-de Bakker, Cornelis A. Eekman, Claudia C. Folman, Henk J. Broxterman, and Herbert M. Pinedo.
- 2191 Priming for T-Cell-mediated Rejection of Established Tumors by Cutaneous DNA Immunization.** Howard M. Ross, Lawrence W. Weber, Siqun Wang, Gregory Piskun, Ruben Dyall, Ping Song, Yoshizumi Takechi, Janko Nikolić-Zugić, Alan N. Houghton, and Jonathan J. Lewis.
- 2197 Isolated Limb Perfusion in the Sarcoma-bearing Rat: A Novel Preclinical Gene Delivery System.** Mira Milas, Barry Feig, Dihua Yu, Noboru Oriuchi, Douglas Cromeens, Tong Ge, Franklin C. Wong, E. Edmund Kim, and Raphael Pollock.
- 2205 The Fas Signaling Pathway Is Functional in Colon Carcinoma Cells and Induces Apoptosis.** Janet A. Houghton, Franklin G. Harwood, Alice A. Gibson, and David M. Tillman.

### Research Articles

- 2211 Expression of Fas (CD95/APO-1) Antigen Induced by Radiation Therapy for Diffuse B-Cell Lymphoma: Immunohistochemical Study.** Yasuhiro Ogawa, Akihito Nishioka, Norihiko Hamada, Masako Terashima, Taisuke Inomata, Shoji Yoshida, Harumichi Seguchi, and Seiji Kishimoto.
- 2217 *In Vivo* Biotherapy of HL-60 Myeloid Leukemia with a Genetically Engineered Recombinant Fusion Toxin Directed against the Human Granulocyte Macrophage Colony-stimulating Factor Receptor.** John P. Perentesis, Roland Gunther, Barbara Waurzyniak, Yuri Yanishevski, Dorothea E. Myers, Onur Ek, Yoav Messinger, Yu Shao, Lisa M. Chelstrom, Elizabeth Schneider, William E. Evans, and Fatih M. Uckun.
- 2229 Altered *p16/MTS1/CDKN2* and *cyclin D1/PRAD-1* Gene Expression Is Associated with the Prognosis of Squamous Cell Carcinoma of the Esophagus.** Hiroya Takeuchi, Soji Ozawa, Nobutoshi Ando, Chih-Horng Shih, Kazuo Koyanagi, Masakazu Ueda, and Masaki Kitajima.
- 2237 Prospective Detection of Preclinical Lung Cancer: Results from Two Studies of Heterogeneous Nuclear Ribonucleoprotein A2/B1 Overexpression.** Melvyn S. Tockman, James L. Mulshine, Steven Piantadosi, Yener S. Erozan, Prabodh K. Gupta, John C. Ruckdeschel, Philip R. Taylor, Tatyana Zhukov, Wei-Hong Zhou, You-Lin Qiao, and Shu-Xiang Yao, for the Lung Cancer Early Detection Work Group Investigators and the Yunnan Tin Corporation Investigators.
- 2247 Expression of Cyclin D1, but not Cyclins E and A, Is Related to Progression in Bilharzial Bladder Cancer.** Iman Osman, Howard Scher, Zuo-Feng Zhang, Timothy J. Soos, Reda Hamza, Saad Eissa, Hussien Khaled, Andrew Koff, and Carlos Cordon-Cardo.
- 2253 Prognostic Significance of Glutathione S-Transferase  $\pi$  Expression and Subcellular Localization in Human Gliomas.** Francis Ali-Osman, Janet M. Brunner, Tetzner M. Kutluk, and Kenneth Hess.

- 2263 Prognostic Significance of Urokinase-type Plasminogen Activator Expression in Squamous Cell Carcinomas of the Esophagus.** Michael Torzewski, Mario Sarbia, Patrick Verreet, Philipp Dutkowski, Hansjörg Heep, Reinhart Willers, and Helmut E. Gabbert.
- 2269 Loss of the Cyclin-dependent Kinase Inhibitor p27<sup>Kip1</sup> Protein in Human Prostate Cancer Correlates with Tumor Grade.** Yanping Guo, Geoffrey N. Sklar, Andrew Borkowski, and Natasha Kyprianou.
- 2275 Molecular Inhibition of Phospholipase C $\gamma$  Signaling Abrogates DU-145 Prostate Tumor Cell Invasion.** Timothy Turner, Mark Van Epps-Fung, Jareer Kassis, and Alan Wells.
- 2283 Abrogation of Tumorigenicity and Metastasis of Murine and Human Tumor Cells by Transfection with the Murine *IFN- $\beta$*  Gene: Possible Role of Nitric Oxide.** Keping Xie, Diane Bielenberg, Suyun Huang, Lei Xu, Thomas Salas, Shin-Hun Juang, Zhongyun Dong, and Isaiah J. Fidler.
- 2295 Loss of Uteroglobin Expression in Prostate Cancer: Relationship to Advancing Grade.** Ashani T. Weeraratna, Jaime A. Cajigas, Arnold Schwartz, Erik G. Enquist, Michael J. Manyak, and Steven R. Patierno.
- 2301 Immunohistochemical Study of c-fos-positive Lymphocytes Infiltrated into Human Squamous Cell Carcinomas of the Head and Neck during Radiation Therapy and Its Clinical Significance.** Yasuhiro Ogawa, Akihito Nishioka, Norihiko Hamada, Masako Terashima, Taisuke Inomata, Shoji Yoshida, Harumichi Seguchi, and Seiji Kishimoto.
- 2309 Increased Expression of *S100A4*, a Metastasis-associated Gene, in Human Colorectal Adenocarcinomas.** Keizo Takenaga, Hayao Nakanishi, Katsunori Wada, Masayoshi Suzuki, Osamu Matsuzaki, Akira Matsuura, and Hideya Endo.
- 2317 Toward the Validation of Aneuploidy Detection by Fluorescence *in Situ* Hybridization in Bladder Cancer: Comparative Analysis with Cytology, Cytogenetics, and Clinical Features Predicts Recurrence and Defines Clinical Testing Limitations.** Feiyu F. Zhang, Daniel A. Arber, Timothy G. Wilson, Mark H. Kawachi, and Marilyn L. Slovak.
- 2329 Correlation between the Expression of Apoptosis-related bcl-2 and p53 Oncoproteins and the Carcinogenesis and Progression of Breast Carcinomas.** Guo-Jun Zhang, Izo Kimijima, Rikiya Abe, Masahiko Kanno, Naoto Katagata, Kiyoshi Hara, Takanori Watanabe, and Atsuo Tsuchiya.
- 2337 High-Dose Infusional Doxorubicin and Cyclophosphamide: A Feasibility Study of Tandem High-Dose Chemotherapy Cycles without Stem Cell Support.** Robert J. Morgan, Jr., James H. Doroshow, Kalyanasundaram Venkataraman, Karen Chang, James Raschko, George Somlo, Lucille Leong, Merry Tetef, Stephen Shibata, Victor Hamasaki, Kim Margolin, Stephen Forman, Steven Akman, Paul Coluzzi, Chul Ahn, Lawrence Weiss, Uday Gadgil, and Jonathan Harrison.
- 2347 Phase I Trial of Orally Administered Pentosan Polysulfate in Patients with Advanced Cancer.** John L. Marshall, Anton Wellstein, James Rae, Robert J. DeLap, Kim Phipps, John Hanfelt, Manasses K. Yunmbam, Jim X. Sun, Kenneth L. Duchin, and Michael J. Hawkins.

- 2355** Effects of a  $\beta$ -Human Chorionic Gonadotropin Subunit Immunogen Administered in Aqueous Solution with a Novel Nonionic Block Copolymer Adjuvant in Patients with Advanced Cancer. Pierre L. Triozzi, Vernon C. Stevens, Wayne Aldrich, John Powell, Charles W. Todd, and Mark J. Newman.
- 2363** Phase I and Pharmacological Trial of Fazarabine (Ara-AC) with Granulocyte Colony-stimulating Factor. Richard M. Goldberg, Joel M. Reid, Matthew M. Ames, Jeff A. Sloan, Joseph Rubin, Charles Erlichman, Mary J. Kuffel, and Thomas R. Fitch.
- 2371** Phase II Trial of Alternating Weekly Chemohormonal Therapy for Patients with Androgen-independent Prostate Cancer. Julie A. Ellerhorst, Shi-Ming Tu, Robert J. Amato, Laury Finn, Randall E. Millikan, Lance C. Pagliaro, Angela Jackson, and Christopher J. Logothetis.
- 2377** Tallimustine, an Effective Antileukemic Agent in a Severe Combined Immunodeficient Mouse Model of Adult Myelogenous Leukemia, Induces Remissions in a Phase I Study. Miloslav Beran, Sima Jeha, Susan O'Brien, Elihu Estey, Lauren Vitek, Maria Grazia Zurlo, Mary Beth Rios, Michael Keating, and Hagop Kantarjian.
- 2385** Imaging of Somatostatin Receptors by Indium-111-Pentetreotide Correlates with Quantitative Determination of Somatostatin Receptor Type 2 Gene Expression in Neuroblastoma Tumors. Vittorio Briganti, Roberta Sestini, Claudio Orlando, Gabriella Bernini, Giuseppe La Cava, Angela Tamburini, Claudia Casini Raggi, Mario Serio, and Mario Maggi.
- 2393** Pharmacokinetics of 3-Methyl-(triazene-1-yl)imidazole-4-carboximide following Administration of Temozolomide to Patients with Advanced Cancer. Joel M. Reid, David C. Stevens, Joseph Rubin, and Matthew M. Ames.
- 2399** Changes in Messenger RNA Expression of Protein Kinase A Regulatory Subunit  $\alpha$  in Breast Cancer Patients Treated with Tamoxifen. William R. Miller, Martin J. Hulme, John M. S. Bartlett, Janis MacCallum, and J. Michael Dixon.
- 2405** Altered Gene Expression in Drug-resistant Human Breast Cancer Cells. Katja Wosikowski, Danita Schuurhuis, Geert J. P. L. Kops, Miguel Saceda, and Susan E. Bates.
- 2415** Adenovirus-mediated Delivery of p16 to p16-deficient Human Bladder Cancer Cells Confers Chemoresistance to Cisplatin and Paclitaxel. Jon Grim, Anna D'Amico, Sandra Frizelle, Joan Zhou, Robert A. Kratzke, and David T. Curiel.
- 2425** Induction of Antitumor Cytotoxic T Lymphocytes from the Peripheral Blood Mononuclear Cells of Cancer Patients Using HLA-A2-restricted MAGE-3 Peptide *in Vitro*. Tatsuo Fujie, Fumiaki Tanaka, Masaki Mori, Kazutoh Takesako, Keizo Sugimachi, and Tsuyoshi Akiyoshi.
- 2431** Docetaxel Enhances Tumor Radioresponse *in Vivo*. Kathryn A. Mason, Nancy R. Hunter, Mira Milas, James L. Abbruzzese, and Luka Milas.
- 2439** Phenotypic Stability of a Cytotoxic T-Cell Line Directed against an Immunodominant Epitope of Human Carcinoembryonic Antigen. Kwong Y. Tsang, MingZhu Zhu, Carol A. Nieroda, Pierpaolo Correale, Sam Zaremba, J. Michael Hamilton, David Cole, Chan Lam, and Jeffrey Schlom.
- 2451** Are Angiogenic Factors, Cytokines, and Soluble Adhesion Molecules Prognostic Factors in Patients with Renal Cell Carcinoma? Christine Dosquet, Marie-Claude Coudert, Eric Lepage, Jean Cabane, and François Richard.
- 2459** *O*<sup>6</sup>-Methylguanine-DNA Methyltransferase Protein Levels in Pediatric Brain Tumors. Suradej Hongeng, Thomas P. Brent, Robert A. Sanford, Hao Li, Larry E. Kun, and Richard L. Heideman.
- 2465** Germ-Line *BRCA1* Mutation Is an Adverse Prognostic Factor in Ashkenazi Jewish Women with Breast Cancer. William D. Foulkes, Nora Wong, Jean-Sebastien Brunet, Louis R. Bégin, Jian Chun Zhang, John J. Martinez, Florence Rozen, Patricia N. Tonin, Steven A. Narod, Stephen E. Karp, and Michael N. Pollak.
- 2471** Biological and Clinical Significance of Concurrent *p53* Gene Alterations, *MDR1* Gene Expression, and S-Phase Fraction Analyses in Breast Cancer Patients Treated with Primary Chemotherapy or Radiotherapy. Sylvie Chevillard, Jérôme Lebeau, Pierre Pouillart, Claudia de Toma, Chérif Beldjord, Bernard Asselain, Jerzy Klijanienko, Alain Fourquet, Henri Magdélénat, and Philippe Vielh.
- 2479** Telomerase Activity in Pancreatic Juice Differentiates Ductal Carcinoma from Adenoma and Pancreatitis. Nobuhiro Suehara, Kazuhiro Mizumoto, Masao Tanaka, Hideaki Niiyama, Kazunori Yokohata, Yohei Tominaga, Hideo Shimura, Tsuyoshi Muta, and Naotaka Hamasaki.
- 2485** Comparative Evaluation of Angiogenesis Assessment with Anti-Factor-VIII and Anti-CD31 Immunostaining in Non-Small Cell Lung Cancer. Alexandra Giatromanolaki, Michael I. Koukourakis, Dimitrios Theodossiou, Kalypto Barbatis, Ken O'Byrne, Adrian L. Harris, and Kevin C. Gatter.
- 2493** Establishment of Two Human Prostate Cancer Cell Lines Derived from a Single Bone Metastasis. Nora M. Navone, Matilde Olive, Mustafa Ozen, Rodney Davis, Patricia Troncoso, Shi-Ming Tu, Dennis Johnston, Allan Pollack, Sen Pathak, Andrew C. von Eschenbach, and Christopher J. Logothetis.
- 2501** Immunoglobulins D and M Multiple Myeloma Variants Are Heavily Mutated. Nadine Juge-Morineau, Carlo Heirman, Marleen Bakkus, Benjamin Van Camp, Ronald Malfait, Jean-Luc Harousseau, Kris Thielemans, and Régis Bataille.
- 2507** Androgens Regulate Vascular Endothelial Growth Factor Content in Normal and Malignant Prostatic Tissue. Ingrid B. J. K. Joseph, Joel B. Nelson, Samuel R. Denmeade, and John T. Isaacs.
- 
- 2513** AACR Bulletin Board  
Institution of Page Changes  
Annual Meeting  
Gertrude B. Elion Cancer Research Award  
AACR Research Fellowships  
AACR Special Conferences in Cancer Research
- 
- Index to Volume 3
- 
- 2515** Acknowledgment to Reviewers
- 2519** Author Index
- 2527** Subject Index
- i Instructions for Authors

## Foundations of Clinical Cancer Research: Perspective for the 21st Century

### Symposium Program

#### Introduction

Foreword	
<i>Evan M. Hersh</i> .....	2550
Foundations of Clinical Cancer Research: Perspective for the 21st Century	
<i>Evan M. Hersh</i> .....	2551
Confrontation, Passion, and Personalization	
<i>Emil Frei III</i> .....	2554
The Future of Clinical Cancer Research in the Next Millennium	
<i>Emil J Freireich</i> .....	2563

#### Session I: Scientific Basis of Clinical Trials

*Chairperson: Michael Rosenblum*

The Wilms' Tumor Gene <i>WT1</i> Can Regulate Genes Involved in Sex Determination and Differentiation: <i>SRY</i> , Müllerian-inhibiting Substance, and the Androgen Receptor	
<i>Ryuji Shimamura, Gail C. Fraizer, Jan Trapman, Yun-fai C. Lau, and Grady F. Saunders</i> .....	2571
Cytokine Deregulation in Hematological Malignancies: Clinical and Biological Implications	
<i>Razelle Kurzrock</i> .....	2581
Clinical Trials in Cancer	
<i>James F. Holland</i> .....	2585
The Scientific Basis of Clinical Trials: Statistical Aspects	
<i>Edmund A. Gehan</i> .....	2587
Prognostic Factors in Clinical Cancer Trials	
<i>Elihu Estey</i> .....	2591

#### Session II: Developmental Therapeutics

*Chairperson: Sewa Legha*

Recreating an Environment for Clinical Discovery	
<i>Jordan U. Gutterman</i> .....	2594
Leukemia: A Model for Drug Development	
<i>Michael J. Keating</i> .....	2598
Advances in Therapy of Multiple Myeloma: Lessons from Acute Leukemia	
<i>Bart Barlogie</i> .....	2605
Drug Development in Solid Tumors: Personal Perspective of Dr. Emil J Freireich's Contributions	
<i>Paul P. Carbone</i> .....	2614
Advances in the Biological Therapy and Gene Therapy of Malignant Disease	
<i>Evan M. Hersh and Alison T. Stopeck</i> .....	2623

#### Session III: Combined Modality Therapy

*Chairperson: Andrew Burgess*

Testicular Cancer: An Oncological Success Story	
<i>Lawrence H. Einhorn</i> .....	2630

Multimodality Therapy for Locally Advanced and Limited Stage IV Breast Cancer: The Impact of Effective Non-Cross-Resistant Late-Consolidation Chemotherapy <i>George R. Blumenschein, Alfred DiStefano, Jess Caderao, Barry Firstenberg, John Adams, Louis H. Schweichler, and Lee Drinkard</i> .....	2633
Combined Modality Therapy of Lung Cancer <i>Robert B. Livingston</i> .....	2638
Freireich's Laws in the Treatment of Sarcomas <i>Robert S. Benjamin</i> .....	2648
Can We Cure Indolent Lymphomas? <i>Fernando Cabanillas</i> .....	2655

### Session IV: Supportive Care

*Chairperson: Roman Perez-Soler*

The Evolution of Antibiotic Therapy for Neutropenic Patients <i>Gerald P. Bodey</i> .....	2660
Hematopoietic Supportive Care <i>Jeane Hester</i> .....	2666
High-Dose Chemotherapy with Busulfan, Cyclophosphamide, and Etoposide as Conditioning Regimen for Allogeneic Bone Marrow Transplantation for Patients with Acute Myeloid Leukemia in First Complete Remission <i>Axel Rolf Zander, Carolina Berger, Nicolaus Kröger, Marcus Stockschröder, William Krüger, Martin Horstmann, Jan Grimm, Wolfgang Zeller, Hartmut Kabisch, Rudolf Ertmann, Petra Schönrock, Rolf Kuse, Dietrich Braumann, Hans-Jochen Illiger, Walter Fiedler, Maike de Witt, Klaus Dieter Hossfeld, and Hans Josef Weh</i> .....	2671

### Session V: Exploitable Molecular Mechanisms

*Chairperson: Martin Raber*

Toward a Leukemia Treatment Strategy Based on the Probability of Stem Cell Death: An Essay in Honor of Dr. Emil J Freireich <i>Ernest A. McCulloch</i> .....	2676
Prospects for Cytokine and Chemokine Biotherapy <i>Joost J. Oppenheim, William J. Murphy, Oleg Chertov, Volker Schirmacher, and Ji Ming Wang</i> .....	2682
Oncogenes and Tumor Suppressor Genes: Therapeutic Implications <i>Sanford A. Stass and A. James Mixson</i> .....	2687
Disorders in Cell Circuitry Associated with Multistage Carcinogenesis: Exploitable Targets for Cancer Prevention and Therapy <i>I. Bernard Weinstein, Martin Begemann, Ping Zhou, Edward K-H. Han, Alessandro Sgambato, Yuichiro Doki, Nadir Arber, Marco Ciaparrone, and Hirofumi Yamamoto</i> .....	2696
Epidermal Growth Factor Receptor Inhibition by a Monoclonal Antibody as Anticancer Therapy <i>John Mendelsohn</i> .....	2703

### Summary

Summary of the First Emil J Freireich Symposium <i>Robert C. Bast, Jr.</i> .....	2708
-------------------------------------------------------------------------------------	------

**Supplemental Material**

Who Took the Clinical Out of Clinical Research?—Mouse <i>versus</i> Man: Seventh David A. Karnofsky Memorial Lecture—1976 <i>Emil J Freireich</i> .....	2711
Chronic Myelogenous Leukemia—Progress at the M. D. Anderson Cancer Center over the Past Two Decades and Future Directions: First Emil J Freireich Award Lecture <i>Hagop M. Kantarjian, Moshe Talpaz, Susan O'Brien, Razelle Kurzrock, Jordan Gutterman, Michael J. Keating, Kenneth B. McCredie, and Emil J Freireich</i> .....	2723
Author Index .....	2734

# Clinical Cancer Research

**3 (12)**

*Clin Cancer Res* 1997;3:2187-2734.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/3/12.citation>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/3/12.citation>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.